Taisho Pharmaceutical
 | |
 Taisho Pharmaceutical head office building | |
Native name | 大正製薬ホールディングス株式会社 |
|---|---|
Romanized name | Taishō Seiyaku Hōrudingusu kabushiki gaisha |
| Company type | Public KK |
| TYO: 4581 | |
| ISIN | JP3442850008 |
| Industry | Pharmaceutical |
| Founded | October 12, 1912 |
| Headquarters | Toshima-ku, Tokyo 170-8655 , Japan |
Area served | Worldwide |
Key people | Akira Uehara (President and CEO) |
| Products | |
| Revenue |  JPY 280 billion (FY 2017)
(US$ 2.6 billion) (FY 20177) |
| JPY 31.6 billion (FY 2017)
(US$ 298 million) (FY 2017) | |
| Owner | Uehara family (33.52%) |
Number of employees | 6,340 (consolidated, as of March 31, 2018) |
| Website | www.taisho.co.jp |
| Footnotes / references [1][2][3] | |
Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社, Taishō Seiyaku Kabushiki-gaisha), commonly known as Taisho, is a Japanese multinational pharmaceutical company based in Tokyo.[3]
History
[edit]Taisho was established in 1912 as Taisho Seiyakusho to produce over-the-counter drugs. In 1928 the company changed its name to Taisho Pharmaceutical Co., Ltd. and in 1955 moved into prescription drug R&D. It introduced its over-the-counter medications like cough suppressant in 1927, pain reliever in 1967 and an antiulcer agent in 1984.[4] In 2019 Taisho bought French pharmaceutical manufacturer UPSA from Bristol Myers Squibb.[5]
The company was delisted from the Tokyo Stock Exchange ca. April 2024 following a successful management buyout.
Products
[edit]The company's principal line of business is over-the-counter (OTC) medicines, where it markets the brands Lipovitan-D, Pabron, Colac, Contac, Tempra, UPSA, Vicks and Kampo In prescription pharmaceuticals, the company's most successful product to date has been the macrolide antibiotic clarithromycin. The company's branded version of the drug, Clarith, was launched in Japan in 1991. For clarithromycin distribution outside Japan Taisho licensed clarithromycin to Abbott Laboratories.
Ownership
[edit]Taisho Pharmaceutical's stock is traded on the Tokyo Stock Exchange and the principal owners of the firm are the Uehara family name.[citation needed]
Sponsorships
[edit]Taisho has sponsored the Japan national rugby union team since 2001.[6] The company was also an Official Sponsor of the Rugby World Cup 2019, which took place in Japan.[7]
References
[edit]- ^ "Corporate Data". Taisho Pharmaceutical. Retrieved March 6, 2019.
- ^ "About the company". Financial Times. Retrieved March 6, 2019.
- ^ a b "Company Profile". Nikkei Asian Review. Nikkei Inc. Retrieved March 6, 2019.
- ^ A. Colditz, Graham (September 12, 2007). Encyclopedia of Cancer and Society. SAGE Publications. pp. 867–868. ISBN 978-1-4522-6561-2.
- ^ "Taisho Pharmaceutical concludes acquisition of UPSA". Pharmaceutical Technology. July 1, 2019. Retrieved July 25, 2022.
- ^ Ikezawa, Hiroshi (September 19, 2018). "Uehara finds common thread between rugby, business". The Japan Times. News2u Holdings. Retrieved March 7, 2019.
- ^ "World Rugby appoints Taisho Pharmaceutical as Rugby World Cup 2019 Official Sponsor". 2019 Rugby World Cup official site. World Rugby. November 1, 2017. Retrieved March 7, 2019.
External links
[edit]
| International | |
|---|---|
| National | |
| Academics | |
 | This article about a Japanese corporation- or company-related topic is a stub. You can help Wikipedia by expanding it. |
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
- Pharmaceutical companies of Japan
- Pharmaceutical companies based in Tokyo
- Companies listed on the Tokyo Stock Exchange
- Pharmaceutical companies established in 1912
- Japanese companies established in 1912
- Japanese brands
- Multinational companies headquartered in Japan
- Japanese company stubs
- Medical company stubs